Company Description

Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders.

Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease.

The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024.

Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Klotho Neurosciences, Inc.

Country	United States
Founded	2019
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	Joseph Sinkule

Contact Details

Address: 13576 Walnut Street, Suite A Omaha, Nebraska 68144 United States
Phone	833 931 6330
Website	klothoneuro.com

Stock Details

Ticker Symbol	KLTO
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1907223
CUSIP Number	49876K103
ISIN Number	US49876K1034
Employer ID	86-2727441
SIC Code	2836

Key Executives

Name	Position
Dr. Joseph Sinkule Pharm.D.	Founder, Chief Executive Officer, Chairman of the Board and Secretary
Jeffrey LeBlanc	Chief Financial Officer
Dr. Shalom Z. Hirschman M.D.	Medical Advisor and Director
Peter J. Moriarty	Chief Business Officer
Dr. Miguel Chillon Rodriguez	Chief Scientific Officer and Consultant

Latest SEC Filings

Date	Type	Title
Jan 12, 2026	PRE 14A	Other preliminary proxy statements
Dec 12, 2025	EFFECT	Notice of Effectiveness
Dec 8, 2025	8-K	Current Report
Dec 5, 2025	S-1	General form for registration of securities under the Securities Act of 1933
Nov 13, 2025	10-Q	Quarterly Report
Nov 6, 2025	S-8	Securities to be offered to employees in employee benefit plans
Sep 30, 2025	424B3	Prospectus
Sep 25, 2025	8-K	Current Report
Sep 25, 2025	8-K	Current Report
Aug 18, 2025	10-Q	Quarterly Report

View All SEC Filings